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Abstract
Current diagnostic screening strategies based on karyotyping or fluorescent in situ hybridization (FISH) for detection of
chromosomal abnormalities in chronic lymphocytic leukemia (CLL) are laborious, time-consuming, costly, and have
limitations in resolution. Multiplex ligation-dependent probe amplification (MLPA) can simultaneously detect copy number
changes of multiple loci in one simple PCR reaction, making it an attractive alternative to FISH. To enhance the clinical
robustness and further harness MLPA technology for routine laboratory operations, we have developed and validated a
protocol for comprehensive, automatic data analysis and interpretation. A training set of 50 normal samples was used to
establish reference ranges for each individual probe, for the calling of statistically significant copy number changes. The
maximum normal ranges of 2 and 3 standard deviations (SD) are distributed between 0.82 and 1.18 (Mean 6 2SD, 95% CI,
P=0.05), and between 0.73 and 1.27 (Mean 6 3SD, 99% CI, P=0.01), respectively. We found an excellent correlation
between MLPA and FISH with 93.6% concordance (P,0.0001) from a testing cohort of 100 clinically suspected CLL cases.
MLPA analyses done on 94/100 patients showed sensitivity and specificity of 94.2% and 92.9%, respectively. MLPA detected
additional copy number gains on 18q21.1 and chromosome 19, and novel micro-deletions at 19q13.43 and 19p13.2 loci in
six samples. Three FISH-failed samples were tested positive by MLPA, while three 13q- cases with a low percentage of
leukemia cells (7%, 12% and 19%) were not detected by MLPA. The improved CLL MLPA represents a high-throughput,
accurate, cost-effective and user-friendly platform that can be used as a first-line screening test in a clinical laboratory.
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Introduction
Advances in cancer genomics allow us to determine and
quantify disease-associated genetic profiles, and to improve clinical
diagnosis/prognosis, tumor classification and ultimately, cancer
therapy [1]. Chromosomal alterations in leukemia have been
shown to have prognostic and predictive value, and are also
important markers of minimal residual disease in the follow-up of
leukemia patients [2]. The complex process that drives the
development of leukemia could rise from several clonal molecular
abnormalities, including copy number gains and losses in the
genome leading to activation of proto-oncogenes and silencing (or
deletion) of tumor suppressor genes, respectively [3,4]. Chronic
lymphocytic leukemia (CLL) is the most common adult leukemia
in developed countries. Specific chromosome copy number
alterations characteristic of CLL, such as loss of the 13q14 region
(with a frequency of 50–60%), trisomy of chromosome 12 (15–
25%), and deletions of 11q22 (10–20%) and 17p13 (5–10%), have
been shown to provide clinically relevant prognostic information
and help identify more aggressive disease [5,6]. Patients with
leukemia cells positive for deletion of 17p13 or 11q22 have an
inferior prognosis compared with normal karyotype or del(13q14),
and appear to be resistant to standard chemotherapy regimens
[5–7]. Trisomy 12 has been associated with an intermediate-to-
unfavorable prognosis [6,7]. Unlike other hematological malig-
nancies, chromosome translocations are relatively rare in CLL [8].
Conventional metaphase karyotyping detects chromosomal
abnormalities in only 40–50% of CLL cases, because obtaining
mitoses representing malignant cells is problematic due to the low
mitotic activity of CLL cells in vitro, even with mitogen
stimulation [9]. Fluorescent in situ hybridization (FISH), which
uses labeled probes targeted to the most commonly altered
genomic regions, has proven to have higher resolution than
traditional cytogenetics. FISH enables detection of alterations in
interphase nuclei and metaphase chromosomes and can reveal
abnormalities in 80% of cases [5–7]. In clinical practice, however,
current FISH analysis is only capable of detecting deletions or
amplifications of sequences larger than 20–50 kb [10], and due to
the high cost of these labeled probes, FISH testing is generally
restricted to 13q14, TP53, ATM and chromosome 12 for CLL
cases. More recently, microarray-based comparative genome
hybridization (array-CGH) and high-density SNP arrays allow
high resolution genome-wide scans for detection of copy-number
variations (CNVs) in a single hybridization [11,12]. Although
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CNVs in individuals, these methods are limited by low
throughput, high cost, and a long turnaround time, and there
remains a need for simple, cost-efficient methods to screen
chromosomal alterations across larger populations.
The PCR-based multiplex ligation-dependent probe amplifica-
tion (MLPA) technique for gene dosage determination offers a
higher throughput, less labor intensive alternative. By comparison
of the abundance of a region of interest in a CLL patient’s cells to
that of a cohort of normal individuals, abnormalities in the
number of copies of each DNA sequence can be identified and
quantified. The introduction of universal primers in MLPA not
only makes multiplex target detection much easier and consistent,
but also significantly cuts down the cost [13,14]. Nevertheless,
detection accuracy is of particular importance if diagnostic
laboratories wish to augment or replace multiprobe FISH with
MLPA. The adoption of this technique will certainly depend on
the robustness of the MLPA technique and the analysis algorithm
used, in order to avoid missed or miscalled results. Here we report
the clinical application of MLPA for the detection of common
genomic deletions and trisomies associated with CLL prognosis, in
direct comparison to FISH. The new strategy we developed for
MLPA data analysis is robust, automated, consistent and cost-
effective. It is our recommendation to establish just such an
analysis protocol to incorporate quality checks, include a reference
cutoff range for each probe, and provide unequivocal scoring
criteria for accurate interpretation of MLPA results. This is the
first report to define these analytical and interpretative parameters
for MLPA application in CLL prognostics.
Materials and Methods
Patient Samples
All patient samples were collected with a signed informed
consent in accordance with Quest Diagnostics Nichols Institute’s
Institutional Review Board (IRB)-approved protocol. Fifty periph-
eral blood samples from healthy donors were used as the training
set for the establishment of MLPA analytical and interpretative
parameters. One hundred referrals for CLL panel testing by FISH
were re-screened using MLPA. The FISH patient samples were
tested as part of the cytogenetics diagnostic service at Quest.
Patient identifiers were removed and replaced by a numbering
scheme allowing all MLPA analysis performed without prior
knowledge to any abnormalities identified by FISH. After MLPA
analysis was completed, all data were decoded to determine
concordance between FISH and MLPA and frequency of each
chromosomal abnormality.
Multiplex Ligation-Dependent Probe Amplification
(MLPA)
DNA extraction. DNA was extracted from blood samples
received in lavender (purple)-top tubes containing ethylene-
diaminetetraacetic acid (EDTA) using the BioRobot EZ1
Workstation (Qiagen, Valencia, CA, USA) following the manu-
facturer’s instructions. All isolated DNA was quantified by
NanoDrop spectrophotometry (NanoDrop, Wilmington, DE,
USA).
MLPA assay. Genomic DNA samples (75–200 ng) were
subjected to PCR reactions containing MLPA P038-A2 CLL
probemix-2, SALSA PCR reagents and polymerase (MRC-
Holland, The Netherlands) following hybridization and ligation
steps. All tests were performed in duplicate in an ABI 9700 PCR
instrument, and amplified PCR products were analyzed by
GeneMapper software v4.0 on an ABI3730 capillary sequencer
(Applied Biosystems, Foster City, CA, USA). The MLPA assay was
performed according to the manufacturer’s protocol, with the
following exceptions: (i) DNA denaturation was done at 98uC for
15 min to increase efficiency, especially for GC-rich sequences; (ii)
40 PCR cycles were performed; (iii) At least five normal control
samples and one negative control were included for each MLPA
run.
MLPA data analysis. The calculation of probe ratios
consisted of a mathematical comparison between relative
quantities of target DNA amplified from a test patient sample, to
those generated in a normal control sample. Analysis of probe
ratios from a pool of 50 normal control samples allowed us to
determine statistical variation within the normal range, and to
assign confidence limits (or standard deviations, SD) to each
diagnostic probe to be called deletions or amplifications. To
streamline the generation and manipulation of probe ratio data,
unique automated Excel spreadsheet was devised and written for
this purpose. The peak area data from GeneMapper software were
imported into a spreadsheet-based automated analysis system. The
system contained a series of quality checks to ensure that samples
failing to pass quality checks will be flagged and not to be reported.
These checks ensure that diagnostic peaks for input DNA amount,
denaturation, hybridization, ligation were in range, and signal
sloping was corrected in both normal and patient samples.
For a test patient sample, a series of ratios was generated for
each diagnostic probe against 13 internal reference probes, rather
than generating a single ratio for each probe by using an average
of reference probes, to minimize differential tail-off effect.
Similarly, on each run, probe ratios were also calculated for each
of at least five normal controls, and the mean of these ratios
formed the denominator in the formula. All probe ratios in normal
controls should not exceed 62 SD of normal range to be
considered valid. The ‘‘median’’ value of a total of 13 normalized
ratios (Patient sample: Normal control) gave the final result for
each individual diagnostic probe:
RATIO~
Median
probe=refprobe 1
Mean probe=refprobe 1 ½ 
,::::::::::::::
probe=refprobe1 3
Mean probe=refprobe1 3 ½ 

Each probe was called ‘‘deleted’’, ‘‘normal’’ or ‘‘amplified’’
depending on whether the ratio fell within or outside of the
established normal range (mean 6 2SD or mean 6 3SD). If more
than 50% of the probe ratios in a particular region indicated a
deletion or amplification, the result for that chromosome region
was called as abnormal. Finally, our spreadsheet-based analysis
system produced a summary table listing each MLPA probe in
each test sample, with color highlighting to indicate a deletion
(Red) or amplification (Blue).
Fluorescence in situ hybridization (FISH)
Samples of peripheral blood from suspected CLL patients were
analyzed with a FISH panel at Quest Diagnostics, using the
following Vysis probes: ATM (11q22.3), p53 (17p13.1), D13S319
(13q14.3)/D13S1020 (13q34), and D12Z3 (CEP 12) (Abbott
Molecular, Abbott Park, IL, USA), according to the manufactur-
er’s instructions. Dual-color fluorescent signals were visualized
under fluorescence microscopy, and for each sample, at least 300
interphase nuclei were analyzed and scored by two independent
investigators. The cutoff values for each individual probe on
peripheral blood and bone marrow samples are: 11q- (6%)/(7%),
+12 (3%)/(3%), 13q- (6%)/(6%), 17p- (10%)/(8%), respectively.
MLPA Detection and Analysis in CLL
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The significance of any change in DNA copy number for
MLPA, and data from MLPA and FISH, were compared with
Fisher’s exact test and nonparametric tests as appropriate. All
probabilities were 2-tailed, and P values ,0.05 were considered
statistically significant.
Results
Establishment of Normal Range for Each Individual MLPA
Probe
In typical CLL MLPA reactions, mixtures composed of up to 40
probes (13 reference and 27 diagnostic) can be used, which makes it
easy to quantitatively assess the copy number changes of different
chromosome regions simultaneously. Dissimilarities in PCR
efficiency between different probes, and probe-to-probe and
sample-to-sample variations are known factors impacting reference
ranges, therefore a common theoretical or arbitrary range for all
probes is inappropriate. Instead of using an arbitrary ratio range
(e.g., 0.75–1.25, 0.8–1.2 or 0.95–1.05) as a single universal cutoff
value for all probes, which is applied in most MLPA studies [13,14],
we set out to establish a normal range for each MLPA probe to
provide a more appropriate baseline from which any copy number
variation (CNV) will be confidently identified in CLL patients. Our
reference ranges were derived from a training pool of 50 healthy
subjects. Each reference range of the 27 diagnostic probes from one
sample was calculated against the other 49 normals. The reference
range data showed a normal distribution in each case, and a narrow
variation in the mean and SD between these normals, with the
Mean 6 2SD value ranging at maximum from 0.82 to 1.18 (95%
CI, P=0.05), and Mean 6 3SD value from 0.73 to 1.27 (99% CI,
P=0.01) (Table 1). For optimal identification of CNVs, we
recommend the use of at least 5 normal genomic DNA samples
as controls in each run, instead of using pooled genomic DNAs
because CNVs in each individual of the pool will become averaged.
As a result, it will reduce the chance to detect real chromosomal
aberrations and therefore a genomic imbalance by MLPA. Further,
each MLPA application should establish its own normal reference
range for each probe, and a standardized methodology should be
used for data computation and analysis. Standardizing MLPA
interpretation in this way should improve the consistency and
accuracy of CNV detection.
Chromosomal Aberrations Detected by MLPA
A testing set of 100 samples from suspected CLL patients was
analyzed for chromosomal abnormalities by MLPA. MLPA
Table 1. Normal reference range established for each individual probe for CLL MLPA.
Probe (gene/chromosome) Normal range (Mean ± 2SD; 95% CI, P=0.05)* Normal range (Mean ± 3SD; 99% CI, P=0.01)*
PTEN1 10q23.3 0.84–1.16 0.76–1.24
PTEN2 10q23.3 0.89–1.11 0.84–1.16
ATM1 11q23 0.85–1.15 0.78–1.22
ATM2 11q23 0.87–1.13 0.80–1.20
ATM3 11q23 0.84–1.16 0.76–1.24
ATM4 11q23 0.88–1.12 0.82–1.18
RDX 11q23 0.91–1.09 0.86–1.15
CD27 12p13.31 0.82–1.18 0.73–1.27
APAF 12q23.1 0.86–1.14 0.83–1.17
IGF1 12q23 0.87–1.13 0.85–1.15
PAH1 12q23 0.89–1.11 0.83–1.17
PAH2 12q23 0.88–1.12 0.82–1.18
RB1 13q14.2 0.87–1.13 0.81–1.19
KCNRG 13q14.3 0.89–1.11 0.84–1.16
DLEU1 1 13q14.3 0.87–1.13 0.80–1.20
DLEU1 2 13q14.3 0.87–1.13 0.80–1.20
DLEU1 3 13q14.3 0.85–1.15 0.78–1.22
ATP7B 13q14.3 0.87–1.13 0.80–1.20
TP53 1 17p13.1 0.83–1.17 0.74–1.26
TP53 2 17p13.1 0.83–1.17 0.81–1.19
TP53 3 17p13.1 0.83–1.17 0.81–1.19
TP53 4 17p13.1 0.84–1.16 0.76–1.24
SMAD4 18q21.1 0.86–1.14 0.79–1.21
CDKN2D 19p13.2 0.86–1.14 0.80–1.20
LDLR 19p13.2 0.89–1.11 0.83–1.16
CCNE1 19q12 0.89–1.11 0.83–1.17
CHMP2 19q13.43 0.89–1.11 0.83–1.17
*Both 95% and 99% confidence interval corresponding to normal DNA content of all probes are presented. These data were based on 50 DNA samples of blood from
healthy controls.
doi:10.1371/journal.pone.0015407.t001
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PLoS ONE | www.plosone.org 3 October 2010 | Volume 5 | Issue 10 | e15407Figure 1. Representative MLPA analysis on CLL patients. (a) Normalized ratio plot (relative copy number, RCN) from a CLL patient with
trisomy 12 and 19, and 13q14 deletions. The data were normalized to those of normal controls. The reference ranges of 2 SD (Mean 6 2SD, 95% CI,
P=0.05) and 3 SD (Mean 6 3SD, 99% CI, P=0.01) for each probe are shown by diamonds and squares, respectively. (b) MLPA analysis of copy
number changes on multiple CLL samples are called and highlighted on a heatmap as blue (gain, $3SD), light blue (gain, $2SD), red (loss, #3SD) and
pink (loss, #2SD) blocks that lie outside of reference ranges of each probe. Note that the high resolution of MLPA in several 13q- and 11q- cases can
pinpoint deletion region down to a single gene level.
doi:10.1371/journal.pone.0015407.g001
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such as 13q14, ATM, and TP53, and trisomy 12. Additionally, the
probe mix also targets other genomic loci with imbalances in CLL,
e.g., 10q23, 18q21 and chromosome 19 [15]. Figure 1 shows a
representative bar graph (A) and a heatmap (B) of relative copy
number changes in CLL patients by MLPA. Although peripheral
blood samples were not subjected to B-cell purification before the
MLPA assay, cases with low percentages of cells carrying genomic
alteration can be reliably detected and scored by our analysis. The
key criteria and guidelines for final call on chromosome copy
number loss or gain are detailed in Table 2. In the validation
samples, deletions in 13q14 with .20% of cells carrying this
aberration, deletions in 11q23 with .12% abnormal cells, or
trisomy 12 with at least 25% leukemia cells were detected and
called by our system. In addition, multiallelic abnormalities from
the same patient, e.g., 13q-/11q-, 13q-/17q-, 13q-/19q13.43-,
12tri/17p- or 12tri/13q-/19+ were identified. In 52 of the 100
testing samples (52%), chromosomal abnormalities were detected
by MLPA: 25 cases (25%) showed loss of the 13q14 region; 8 cases
(8%) showed trisomy of chromosome 12; 3 cases (3%) showed loss
of the ATM gene; 3 cases (3%) showed loss of the TP53 gene; and
13 cases (13%) showed multiallelic imbalance (Table 3). Overall, a
good correlation was found between MLPA and FISH results, and
all abnormalities observed by FISH were also identified by MLPA,
with the exception of three 13q- cases with a prohibitively low
percentage of leukemia cells (7%, 12% and 19% by FISH).
MLPA Detects Genomic Abnormalities Not Identified by
FISH
It is noteworthy to mention that in six of the CLL samples
tested, MLPA detected additional copy number gains on 18q21.1
and chromosome 19, and novel micro-deletions at 19q13.43 and
19p13.2 loci, which FISH probes did not cover (Table 3). Most
importantly, the higher resolution of MLPA was demonstrated in
several 13q- and 11q- cases, in which MLPA was able to pinpoint
deletion of a small region down to a single gene level, for example,
a small deletion that was only detected in the DLEU gene on
13q14.3, but not the adjacent RB1, KCNRG or ATP7B genes.
Another example was a deletion only detected in the ATM gene of
11q23, but not the adjacent RDX genes (Fig. 1B). Our improved
technique should allow the detection of small submicroscopic
losses or gains that FISH will miss.
Concordance between MLPA and FISH
A total of 52 chromosomal alterations for CLL weredetected using
both techniques. MLPA and FISH data were in agreement in 93.6%
of cases (88/94), and the failure rate was 5–6% (3/52) for both
methods (Table 4). Detection of alterations was similar using either
MLPA or FISH (with 93.6% concordance, P,0.0001). MLPA
analyses done on these patients showed sensitivity and specificity of
94.2% and 92.9%, respectively. Discordant results were found in six
samples: three patients with a low percentage of cells (,20%)
carrying 13q14 deletion was detected by FISH, but not by MLPA;
three FISH-failed samples were detected positive by MLPA.
Sensitivity of CLL MLPA
Because different CLL blood and bone marrow samples,
depending on the disease state, contain different percentage of
leukemia cells, the results of normalized ratios from MLPA were
segregated by percentage of FISH-positive leukemia cells. In the
13q14 deletion cases, as the portion of tumor population increased,
the MLPA ratios gradually moved out of the normal ranges of 62o r
3 SD. Leukemia clones with 13q14 deletion have to make up at least
20% (2SD) or 40% (3SD) of the total population in a sample to be
called statistically significant copy number change (Fig. 2A).A mixing
study to determine MLPA sensitivity (or limit of detection) was also
performed. In these experiments, DNA samples with a homozygous
Table 2. MLPA test for CLL: interpretative criteria and calling guidelines.
Normalized probe ratio Calling guidelines Interpretation, p-value
Within Mean 6 2SD Duplicates show .=50% probes in the cluster are within this range Normal
Out of Mean 6 3SD Duplicates show .=1 probe in the cluster are out of this range Deletion or Amplification, P,0.01
Between Mean 6 2SD and Mean 6 3SD Duplicates show .=50% probes in the cluster are within this range Loss or Gain, P,0.05
doi:10.1371/journal.pone.0015407.t002
Table 3. Frequency of genomic alterations detected for each
chromosome in 100 suspected CLL cases by MLPA and FISH.
Genomic alterations MLPA cases (%) FISH cases (%)
13q- 25 (25) 26 (26)
12 Trisomy 8 (8) 8 (8)
11q- 3 (3) 3 (3)
17p- 3 (3) 3 (3)
18q+ 1 (1) NA
19q13.432 1 (1) NA
19p13.22 1 (1) NA
Multiallelic alterations
13q-/11q- 6 (6) 6 (6)
13q-/17p- 3 (3) 3 (3)
13q-/19q13.432 2 (2) NA
13q-/12tri/19+ 1 (1) NA
12tri/17p- 1 (1) 1 (1)
Total cases include cases detected by FISH or by MLPA.
NA, not applicable.
doi:10.1371/journal.pone.0015407.t003
Table 4. Concordance of MLPA with FISH on 94 suspected
CLL specimens.
MLPA, n (%)
FISH Positive Negative Total Concordance P*
Positive 49 (94.2) 3 (5.8) 52 93.6% ,0.0001
Negative 3 (7.1) 39 (92.9) 42 93.6% ,0.0001
*All comparisons used two-tailed Fisher’s exact test.
doi:10.1371/journal.pone.0015407.t004
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to generate testing materials with 0, 10%, 20%, 50%, 75% or 100%
alterations.Figure 2B shows that 13q deletioncan bereliably detected
and called by our MLPA protocol if they are present in at least 20%
of the total DNA consistent with our previous findings. Moreover, it
demonstrates that the reference ranges for each MLPA probe to
distinguish between normal and abnormal, the interpretative criteria,
and the calling guidelines have been set correctly.
Discussion
The present work details a novel comprehensive MLPA
platform for mapping and assessing the significance of chromo-
somal abnormalities in CLL. MLPA can provide detailed
multiplex profiles of chromosomal aberrations in tumor samples
in a relatively short period of time. MLPA data analysis and
interpretation are critical for calling real amplification or deletion
events in each chromosome region. In contrast to most MLPA
studies that applied only a handful normal samples in each
experiment or used arbitrary cutoff ratios (subjective values), our
report represents the first study to (i) develop and validate a
vigorous analytical and scoring criteria for MLPA to robustly map
chromosomal aberrations in CLL, with parameters adapted to the
characteristics of individual probes, (ii) use reference range of each
probe, Mean 6 2SD and 6 3SD (95% CI, P=0.05 and 99% CI,
P=0.01, respectively), to determine statistically significant copy
Figure 2. Correlation between MLPA and FISH analyses on 13q14- samples. (a) Normalized ratios by MLPA were grouped by the
percentage of FISH-identified leukemia clones carrying 13q14 deletion. The distribution of MLPA ratios showed that 13q14- cells must represent at
least 20% (if using 2SD as cutoff) or 40% (if using 3SD as cutoff) of the total population in a sample to be called a statistically significant copy number
change. (b) Mixing study using a homozygous 13q- DNA spiked into normal control DNA to create samples containing 0, 10%, 20%, 50%, 75% or
100% alterations. This study also showed a 20% detection limit on 13q deletion by MLPA.
doi:10.1371/journal.pone.0015407.g002
MLPA Detection and Analysis in CLL
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cover equivocal cases in which the normalized probe ratios fell
between 2SD and 3SD borderlines.
The reference range is generated by randomly selecting a
training subset of 50 healthy individuals, and produces consistent
normal ratios for the determination of genomic imbalance. We
further reduced probe-to-probe and sample-to-sample variations
by segmenting the 13 internal reference probes. This process
correlates 27 diagnostic probes across all 50 normals, assigning the
arithmetic mean and SD of the normalized ratios for each
individual probe to produce highest accuracy in individual event
calls. A large amount of information is encoded by original probe
ratio data, and the reference range is thus established to reduce
that information content to a minimal set of discrete gains, losses,
or neutral copy numbers. Observation of variation within the
control sample pool has allowed us to evaluate performance of the
MLPA method, and optimize application of the technique in
patients with CLL.
Each chromosomal alteration presents different analytical
challenges, not only in dynamic range, but also in their noise
characteristics, which is often overlooked. For example, there are
challenges unique to allelic loss in CLL. First, deletion is restricted
in its size, and second, only two copies of a locus can be lost. This
is different from amplification. The lacking of real magnitude and
interference from normal DNA in the sample, making it difficult to
make a deletion call, and this is further exacerbated for single-copy
events at the margins of signal and noise. The limit of detection
(LOD) of our improved CLL MLPA assay for calling an allelic loss
is approximately 20% of that leukemia clone circulating in the
bloodstream. Although the sensitivity is somewhat lower than the
sensitivity obtained with interphase FISH (5–10%), such detection
level is sufficient for most untreated CLL patients at diagnosis (2,
6). On the other hand, absence of an allelic copy is readily detected
while gains in copy number are more problematic to confirm by
FISH, especially if the distance between the probes is small [16].
This is a key difference between the methods, with MLPA having
the potential to more accurately identify and quantify copy
number gains.
To adapt to the diversity of variation among individual probes,
samples and alterations, we developed and validated a multi-
component scoring scheme for the detection of copy-number
changes on a large repository of suspected CLL samples. MLPA
produced strong concordance (93.6%) with the gold standard,
FISH, without pre-enrichment of malignant B-cells, further
enhancing its clinical utility. Fourty-nine abnormalities identified
by MLPA were previously reported deletions and trisomy. Six
abnormalities were not covered by a standard FISH probe panel.
Among these, CLL MLPA analysis identified a complex
amplification on 18q21.1 containing the SMAD4 gene, and a gain
(trisomy) of chromosome 19, as well as small intragenic deletions at
the 19q13.43 CHMP2 and 19p13.2 CDKN2D loci. Trisomy 19 is a
CLL-associated genomic abnormality observed in ,5% of CLL
cases [15,17]. One of our samples with trisomy 19 also carried a
trisomy of chromosome 12 and a loss of the 13q14 region. Co-
existence of these three aberrations, as well as trisomy 12/19, have
been documented [17,18]. The SMAD4 gene, a member of the
MAD gene family, is involved in TGF-beta signal transduction.
Overexpression of SMAD4 (by 18q21.1 amplification) could
thereby play a role during the development of CLL resistance to
TGF-beta [19,20]. CDKN2D gene (cyclin-dependent kinase
inhibitor 2D) on 19p13.2 belongs to the INK4 family. Members
of the INK4 family play widespread and independent roles in
tumor suppression in a variety of cancers [21]. CHMP2 gene on
19q13.43 belongs to the chromatin-modifying protein/charged
multivesicular body protein family. The gene product is involved
in degradation of surface receptor proteins and formation of
endocytic multivesicular bodies and is required for regulation of
cell cycle progression [22]. Overall, MLPA has the potential to
identify more abnormalities from a single sample than FISH.
Our automated CLL MLPA data processing, analysis and
interpretation strategy has significant clinical advantages, espe-
cially when handling large MLPA data sets, when samples are of
different quality, and when interpretation of MLPA electrophe-
rograms is too complex. Additionally, for tests that could be
applied in the diagnostic setting, turnaround time is a critical
factor. With MLPA, the total process-to-report time, including
data analysis, is 2–3 days compared to 7–10 day for FISH. MLPA
is also cheaper and less labor intensive compared with FISH. In
summary, our improved MLPA offers the advantages of
multiplexing, high-throughput, high resolution and low-cost for
detection of copy number changes over classical karyotyping/
FISH in routine CLL diagnostics.
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